Assessment of Cardiovascular Risk and Inflammatory Markers in Patients with Rheumatoid Arthritis

Not Applicable

• Conditions: rheumatoid arthritis; insulin resistance; C18.452.394.968.500; C05.550.114.154

• Registration Number: RBR-2jvj92
• Lead Sponsor: niversidade Estadual de Londrina

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-05
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients with rheumatoid arthritis who meet the criteria of the American College of Rheumatology 2010.

Exclusion Criteria

Patients with other autoimmune diseases, kidney, heart, liver, diabetes, acute or chronic infectious diseases; use of metformnas and statins, supplements with antioxidant activity.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients with rheumatoid arthritis and insulin resistance have increased disease activity as measured by the Disease Activity Score 28 joints (DAS28); inflammatory process at a higher intensity, measured by ESR, C-reactive protein and serum levels of tumor necrosis factor alpha ; and unfavorable redox status assessed by advanced oxidation protein products, plasma total antioxidant capacity when compared to patients with rheumatoid arthritis without insulin resistance.

Secondary Outcome Measures

Name	Time	Method
Patients using anti-tumor necrosis factor had lower plasma levels of tumor necrosis factor alpha therapy.;Patients taking anti tumor necrosis factor had higher plasma levels of tumor necrosis factor therapy than those who did not use.